Nature Reviews Drug Discovery contents June 2012 Volume 11 Number 6 pp 421-497

Advertisement
Monitor Cell Migration in Real Time Advance your cancer research with the xCELLigence System. Measure cell migration continuously using the CIM-Plate 16. For life science research only. Not for use in diagnostic procedures. Visit: https://www.xCELLigence.roche.com
TABLE OF CONTENTS
June 2012 Volume 11 Number 6		Advertisement
Impact Factor 28.712 *	In this issue Comment News and Analysis Research Highlights Reviews Correspondence Also this month  Featured article: Are sirtuins viable targets for improving healthspan and lifespan? Joseph A. Baur, Zoltan Ungvari, Robin K. Minor, David G. Le Couteur & Rafael de Cabo	Are you looking for new research in pharmaceutical and medicinal chemistry? • Encyclopedia of Drug Metabolism and Interactions An essential reference that every drug developer should have • Burger's Medicinal Chemistry, Drug Discovery and Development Explains how drugs work and how new drugs are discovered and developed • General, Applied and Systems Toxicology Combines traditional and emerging toxicology research in a single source Find out more here
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Relay Technology Management Real time business intelligence and data visualization for the Life Science Industry Trend monitoring and comparative asset analysis  Click here for more information or to arrange a trial.
In this issue p421 | doi:10.1038/nrd3754 Full Text
Comment: Revitalizing psychiatric drug discovery Martin Sarter & Mark Tricklebank p423 | doi:10.1038/nrd3755 Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
The gout pipeline crystallizes Joanne Kotz p425 | doi:10.1038/nrd3748 The gout space is heating up, but is there sufficient room in the market to accommodate multiple new therapeutics? PDF
Can next-generation antibodies offset biosimilar competition? Asher Mullard p426 | doi:10.1038/nrd3749 With the first biosimilar version of a monoclonal antibody now under regulatory review in the European Union, which R&D strategies are innovators relying on to counteract competition? PDF
NEWS IN BRIEF Busy panels recommend Pfizer's tofacitinib, Arena's lorcaserin and more | Roche's dalcetrapib dies, but CETP field carries on | Fuel for the debate on clinical trial shortcomings p429 | doi:10.1038/nrd3750 PDF
BIOBUSINESS BRIEFS Deal watch: Shire increases focus on regenerative medicine Sarah Crunkhorn p430 | doi:10.1038/nrd3767 PDF
BIOBUSINESS BRIEFS Deal watch: Amgen builds secondary hyperthyroidism pipeline Man Tsuey Tse p430 | doi:10.1038/nrd3768 PDF
PATENT WATCH Changes in Australian patent law | Chemical structure does not define obviousness | Sirtuin modulators Charlotte Harrison p432 | doi:10.1038/nrd3751 PDF
AN AUDIENCE WITH Gregory Lip p434 | doi:10.1038/nrd3752 Gregory Lip, a cardiologist at the University of Birmingham Centre for Cardiovascular Sciences, discusses the changing oral anticoagulant landscape. PDF
FROM THE ANALYST'S COUCH Outlook for the next 5 years in drug innovation Roy Berggren, Martin Møller, Rachel Moss, Pawel Poda & Katarzyna Smietana p435 | doi:10.1038/nrd3744 Analysis of industry pipeline data and revenue forecasts highlights several trends in the anticipated output of new drugs and the therapeutic area focus over the next 5 years, including a growth in the average number of new drug approvals annually. PDF
PIPELINE PIONEERS Vismodegib Andrzej Dlugosz, Sid Agrawal & Peter Kirkpatrick p437 | doi:10.1038/nrd3753 First-in-class inhibitor of the Hedgehog signalling pathway approved in the United States for the treatment of basal cell carcinoma. PDF
RESEARCH HIGHLIGHTS Top Gene therapy: Crossing mitochondrial barriers p439 | doi:10.1038/nrd3762 PDF Neurological disorders: Nanoparticle opens door to cerebral palsy treatment p440 | doi:10.1038/nrd3758 PDF Neurodevelopmental disorders: Glutamate blockers show benefit in models of autism spectrum disorders p440 | doi:10.1038/nrd3761 PDF Infectious disease: Pro-resolving lipids offer a helping hand to antibiotics p441 | doi:10.1038/nrd3760 PDF Bone diseases: SEMA3A strikes a balance in bone homeostasis p442 | doi:10.1038/nrd3759 PDF IN BRIEF Bone diseases: Repairing cartilage in osteoarthritis | Stem cells: A model of cardiomyopathy | Obesity and diabetes: CD44 immune receptor linked to diabetes | Adverse events: Linking COX2 to cardiovascular side effects PDF Drug Discovery JOBS of the week Drug Safety Associate Clinical Professionals Senior Drug Safety Analyst 1881 EMD Serono, Inc. Observational, prospective study about the incidence of adverse drug effects in patients with drug-resistence epilepsy Università degli Studi di Firenze- Dipartimento di Scienze Neurologiche e Psichiatriche Global Drug Development Project Manager II Genentech Postdoctoral Fellow in Computational Structure-Based Drug Design Mount Sinai School of Medicine (Zhou Lab) More Science jobs from Drug Discovery EVENT International Conference on Central Nervous System - Drugs Effects & Novel Drug Development 05.-07.09.12 PA, US More science events from
REVIEWS		Top
Are sirtuins viable targets for improving healthspan and lifespan? Joseph A. Baur, Zoltan Ungvari, Robin K. Minor, David G. Le Couteur & Rafael de Cabo p443 | doi:10.1038/nrd3738 The sirtuin proteins have emerged as potential regulators of mammalian lifespan, and are believed to be responsible for the health and longevity-enhancing effects of caloric restriction. Here, Baur and colleagues provide an overview of the sirtuin family, focusing on sirtuin 1 (SIRT1) and its potential to be targeted in the treatment of age-related diseases. They address the controversy surrounding the mechanism of action of resveratrol and the development of more potent SIRT1 activators. Abstract | Full Text | PDF
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Guy Griebel & Florian Holsboer p462 | doi:10.1038/nrd3702 A wealth of preclinical data on the role of neuropeptides in modulating behaviour has encouraged extensive efforts to target neuropeptide receptors for the treatment of psychiatric diseases, but so far clinical studies have not led to marketed drugs. This article analyses research on neuropeptide receptor ligands that have been studied in clinical trials, including agents that target the receptors for tachykinins, corticotropin-releasing factor and vasopressin, and suggests new ways to realize their full potential. Abstract | Full Text | PDF | Supplementary information
Strategies for the discovery and development of therapies for metastatic breast cancer Bedrich L. Eckhardt, Prudence A. Francis, Belinda S. Parker & Robin L. Anderson p479 | doi:10.1038/nrd2372 Metastasis is the main cause of mortality for patients with cancer. For the development of more effective treatments, a better understanding of the mechanisms of metastasis is required. In this Review, Anderson and colleagues discuss the processes underlying metastasis in breast cancer and describe how advances in the identification of relevant signalling pathways and genetic regulators can facilitate the development of novel targeted anti-metastatic drugs. Abstract | Full Text | PDF | Supplementary information
CORRESPONDENCE		Top
Correspondence: A blueprint for an ideal corporate information centre Oliver Renn, Michael Archer, Carmen Burkhardt, Jeannette Ginestet, Henning P. Nielsen, Joanna Woodward & the P-D-R Library Affairs & Copyright Group p497 | doi:10.1038/nrd2973-c1 Full Text | PDF
Advertisement
The nature.com open innovation pavilion now has several research and development Challenges in genetics, molecular cell biology, chemistry, physics, immunology and more! Submit your solution to any of our Challenges for a chance to win cash awards ranging from $5,000 to $1M. Visit the pavilion or become a Solver today!
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.